Stockscreener 앱 받기
44.49
0.74%
-0.33
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
Xenon Pharmaceuticals (NASDAQ:XENE) CEO Ian Mortimer Sells 40,000 Shares - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Up 3.8% – Should You Buy? - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Trading 3.8% HigherHere's Why - MarketBeat
Analysts Conflicted on These Healthcare Names: Lifecore Biomedical (LFCR) and Xenon (XENE) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novavax (NVAX), Xenon (XENE) and Biohaven Ltd. (BHVN) - The Globe and Mail
Commit To Purchase Xenon Pharmaceuticals At $32.50, Earn 25.8% Annualized Using Options - Nasdaq
Harbor Capital Advisors Inc. Has $450,000 Holdings in Xenon Pharmaceuticals Inc. $XENE - Defense World
Xenon announces new data on 48-month azetukalner OLE study data - MSN
Stifel reiterates Buy rating on Xenon Pharmaceuticals stock amid competitor setback - Investing.com Canada
Biohaven Misses The Mark In Depression Trial, Stock Falls - Sahm
Traders Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - MarketBeat
Why (XENE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Can Xenon Pharmaceuticals Inc. stock deliver surprise earnings beatMarket Performance Summary & Stepwise Swing Trade Plans - bolumsonucanavari.com
Pullback Watch: How rising interest rates impact Xenon Pharmaceuticals Inc. stockMarket Sentiment Report & Growth Focused Stock Pick Reports - Улправда
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
Returns Recap: Why Xenon Pharmaceuticals Inc. stock remains undervaluedJuly 2025 PostEarnings & Capital Efficient Trading Techniques - Улправда
Will Xenon Pharmaceuticals Inc. stock outperform tech sector in 20252025 Price Targets & Long Hold Capital Preservation Plans - Улправда
Can Xenon Pharmaceuticals Inc. stock resist sector downturns2025 Price Momentum & Precise Entry and Exit Recommendations - Улправда
Is Xenon Pharmaceuticals Inc. stock attractive for passive investorsPortfolio Update Report & AI Powered Buy and Sell Recommendations - Улправда
Why Xenon Pharmaceuticals Inc. stock remains undervalued2025 Market Overview & Fast Entry High Yield Stock Tips - Улправда
How rising interest rates impact Xenon Pharmaceuticals Inc. stockForecast Cut & High Conviction Buy Zone Alerts - Улправда
Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout (NASDAQ:XENE) - Seeking Alpha
Xenon Pharmaceuticals Inc. $XENE is Braidwell LP's 7th Largest Position - MarketBeat
Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch PreparationSlideshow (NASDAQ:XENE) 2025-12-12 - Seeking Alpha
Xenon Pharmaceuticals (NASDAQ:XENE) Given New $48.00 Price Target at Wells Fargo & Company - Defense World
Wells Fargo Maintains Xenon Pharmaceuticals (XENE) Overweight Recommendation - Nasdaq
XENE Stock Update: Wells Fargo Raises Price Target to $48 | XENE - GuruFocus
Russell Investments Group Ltd. Decreases Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - MarketBeat
Xenon projects top line X-TOLE2 data in early 2026 as enrollment surpasses target, expanding late-stage pipeline - MSN
Transcript : Xenon Pharmaceuticals Inc.Special Call - marketscreener.com
Ian Mortimer Sells 10,830 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock - MarketBeat
Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) CEO Sells 14,375 Shares of Stock - MarketBeat
Ian Mortimer, Xenon Pharma CEO, sells $1.14m in shares By Investing.com - Investing.com South Africa
Ian Mortimer, Xenon Pharma CEO, sells $1.14m in shares - Investing.com
Xenon Pharmaceuticals President & CEO Ian Mortimer Sells Shares - TradingView — Track All Markets
Xenon Pharmaceuticals unveils promising long-term epilepsy treatment data - MSN
CEO Mortimer Files To Sell 10,830 Of Xenon Pharmaceuticals Inc [XENE] - TradingView — Track All Markets
Marshall Wace LLP Acquires 262,109 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 1-Year High – Here’s What Happened - Defense World
Is Xenon Pharmaceuticals (XENE) Quietly Reframing Its Epilepsy Bet Through Equity Awards and New Data? - Yahoo Finance
Xenon Pharmaceuticals issues equity inducement grants to new employees - MSN
New York State Common Retirement Fund Purchases 24,100 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Rhumbline Advisers Grows Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 52-Week HighHere's What Happened - MarketBeat
Xenon Pharmaceuticals Inc. $XENE is Affinity Asset Advisors LLC's 3rd Largest Position - MarketBeat
Xenon Pharmaceuticals Inc. $XENE is Affinity Asset Advisors LLC’s 3rd Largest Position - Defense World
Evaluating Xenon Pharmaceuticals (XENE)’s Valuation After Its Recent Share Price Rebound - Sahm
Xenon Pharmaceuticals stock hits 52-week high at 45.09 USD By Investing.com - Investing.com India
XENE Unveils Promising Data on Epilepsy Treatment Advances - GuruFocus
Xenon Pharmaceuticals stock hits 52-week high at 45.09 USD - Investing.com
Xenon Pharmaceuticals Unveils Promising Long-Term Epilepsy Treatment Data - TipRanks
0.57%
자본화:
|
볼륨(24시간):